Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as
nonalcoholic fatty liver disease, is becoming a significant contributor to chronic liver disease …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent and challenging
disease associated with a significant health and economic burden. MAFLD has been …

Obesity, the metabolic syndrome, and metabolic dysfunction-associated fatty liver disease
(MAFLD) can be portrayed as transmissible diseases. Indeed, they can be induced, in …

Numerous studies show a modification of the gut microbiota in patients with obesity or
diabetes. Animal studies have also shown a causal role of gut microbiota in liver metabolic …

Metabolically associated fatty liver disease (MAFLD) is a common cause of chronic liver
disease, the hepatic manifestation of metabolic syndrome. Despite the increasing incidence …

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver
disease globally and imposed a heavy economic burden on society and individuals. To …

In 2020, a revised definition of fatty liver disease associated with metabolic dysfunction
(MAFLD) was proposed to replace non-alcoholic fatty liver (NAFLD). Liver steatosis and at …

Nonalcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver in the absence
of secondary causes. NAFLD is a multifactorial disease that results from the interaction of …

Metabolic dysfunction, including most notably type 2 diabetes mellitus (T2D), forms a major
component of obesity-associated morbidity and mortality. 1 Insulin resistance and …

Metabolic-dysfunction-associated fatty liver disease (MAFLD) is the recent nomenclature
designation that associates the condition of non-alcoholic fatty liver disease (NAFLD) with …